Details of the Drug

General Information of Drug (ID: DMCKNBA)

Drug Name
Lufironil
Synonyms Hoe-077
Indication
Disease Entry ICD 11 Status REF
Liver cirrhosis DB93.1 Phase 2 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 281.31
Logarithm of the Partition Coefficient (xlogp) -0.6
Rotatable Bond Count (rotbonds) 8
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 5
Chemical Identifiers
Formula
C13H19N3O4
IUPAC Name
2-N,4-N-bis(2-methoxyethyl)pyridine-2,4-dicarboxamide
Canonical SMILES
COCCNC(=O)C1=CC(=NC=C1)C(=O)NCCOC
InChI
InChI=1S/C13H19N3O4/c1-19-7-5-15-12(17)10-3-4-14-11(9-10)13(18)16-6-8-20-2/h3-4,9H,5-8H2,1-2H3,(H,15,17)(H,16,18)
InChIKey
JUCNGMPTCXPMNB-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
60788
CAS Number
128075-79-6
TTD ID
D01NCH
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prolyl 4-hydroxylasesubunit alpha-1 (P4HA1) TTNH25W P4HA1_HUMAN Modulator [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Interference in clinical laboratory tests, with special regard to the bilirubin assay: effects of a metabolite of the new prolyl 4-hydroxylase inhibitor, Lufironil. Eur J Clin Chem Clin Biochem. 1994Jul;32(7):515-20.